Morgan Stanley, BofA Securities and Cowen acted as joint book-running managers for the offering. In this offering, the underwriters placed more than 14 Mio shares in ADCT in the public, including the over-allotment option, at a price of USD 19.00 per share, resulting in gross proceeds for the company of approx. USD 267 Mio.
Lenz & Staehelin advised the underwriters on the Swiss law aspects of the transaction. The team consisted of partner Jacques Iffland (Head of capital markets Geneva – pictured) and senior associate Federico Trabaldo Togna (corporate and m&a, capital markets).
As previously reported by Legalcommunity.ch, Homburger advised ADC Therapeutics. The team was led by partner Dieter Gericke (corporate and m&a).